...
首页> 外文期刊>Vaccine >A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens
【24h】

A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens

机译:使用一系列已建立的和新一代疫苗抗原对明矾替代佐剂的初步评估

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Although alum is the most commonly used vaccine adjuvant, it has some limitations for use with the next generation recombinant antigens. We explored the use of alternative adjuvant formulations (poly lactide co-glycolide (PLG) microparticles, MF59 emulsion, CAP and l-tyrosine suspension) in comparison with five different vaccine antigens--namely, diphtheria toxoid (DT), tetanus toxoid (TT), HBsAg, Men C conjugate and MB1. The results indicated that although alum was optimal for bacterial toxoid based vaccines, it was not highly potent for MB1, Men C or HBsAg antigens. MF59 emulsion stood out as a good alternative to alum for TT, HBsAg, MB1 and Men C vaccines. On the other hand l-tyrosine suspension and CAP did not enhance immune responses over alum with most antigens. PLG microparticles were comparable or better than alum with both MB1 and Men C conjugate vaccine. The study indicates that it is possible to replace alum with other adjuvant formulations like MF59 and PLG and maintain and/or improve immune responses with some vaccine antigens.
机译:虽然明矾是最常用的疫苗佐剂,但与下一代重组抗原一起使用时仍存在一些局限性。我们与五种不同的疫苗抗原(即白喉类毒素(DT),破伤风类毒素(TT)相比,探讨了替代性佐剂制剂(聚丙交酯-乙交酯(PLG)微粒,MF59乳剂,CAP和l-酪氨酸悬浮液)的使用),HBsAg,Men C结合物和MB1。结果表明,尽管明矾最适合用于细菌类毒素疫苗,但对MB1,Men C或HBsAg抗原的作用不是很高。 MF59乳剂可作为明矾替代TT,HBsAg,MB1和Men C疫苗的良好替代品。另一方面,与大多数抗原相比,左酪氨酸悬浮液和CAP不能增强明矾的免疫反应。与MB1和Men C结合疫苗相比,PLG微粒与明矾相当或更好。研究表明,可以用其他佐剂配方(如MF59和PLG)代替明矾,并维持和/或改善某些疫苗抗原的免疫反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号